IPO registrations (S-1, F-1) · Registrants

Lyra Therapeutics, Inc.

SEC CIK
1327273 · filings on EDGAR ↗
Former names
480 Biomedical, Inc. (2012–2016); Arsenal Vascular, Inc. (2011–2011); Arsenal Medical, Inc. (2009–2010); WMR Biomedical Inc (2005–2009)
Registration
Form S-1, first filed 2020-03-06, last 2025-07-22; 2 initial registrations, 1 amendment
Outcome
Final prospectus filed 2020-05-01; declared effective 2020-04-30
Industry (SIC)
Surgical & Medical Instruments & Apparatus 3841
Incorporated in
DE
Business address
480 ARSENAL WAY, Watertown, MA 02472
EDGAR entity type
operating
Insiders and CEO pay
Lyra Therapeutics, Inc. on the corporate pages

Offering terms

Proposed price range
$14.00–$16.00 per share (S-1/A filed 2020-04-27)
Final price
$16.00 per share, within the range (424B4 filed 2020-05-01, an initial public offering)
Shares sold
3,500,000
Gross proceeds
$56,000,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol LYRA
Lead underwriters
BofA Securities; Jefferies (1,225,000 shares); William Blair (525,000 shares)
Syndicate
BTIG (350,000)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 13

FiledFormWhat it isName as filedEDGAR
2020-03-06S-1S-1 (registration)Lyra Therapeutics, Inc.0001193125-20-065213 ↗
2020-04-27S-1/AS-1/A (amendment)Lyra Therapeutics, Inc.0001193125-20-120337 ↗
2020-04-30EFFECTEFFECT (declared effective)Lyra Therapeutics, Inc.9999999995-20-000931 ↗
2020-05-01424B4424B4 (final prospectus)Lyra Therapeutics, Inc.0001193125-20-131089 ↗
2021-05-20EFFECTEFFECT (declared effective)Lyra Therapeutics, Inc.9999999995-21-002044 ↗
2022-05-20EFFECTEFFECT (declared effective)Lyra Therapeutics, Inc.9999999995-22-001554 ↗
2023-07-07EFFECTEFFECT (declared effective)Lyra Therapeutics, Inc.9999999995-23-002032 ↗
2024-04-01EFFECTEFFECT (declared effective)Lyra Therapeutics, Inc.9999999995-24-000816 ↗
2025-07-22S-1S-1 (registration)Lyra Therapeutics, Inc.0001193125-25-162669 ↗
2025-07-30EFFECTEFFECT (declared effective)Lyra Therapeutics, Inc.9999999995-25-002415 ↗
2026-03-26EFFECTEFFECT (declared effective)Lyra Therapeutics, Inc.9999999995-26-000934 ↗
2026-03-26EFFECTEFFECT (declared effective)Lyra Therapeutics, Inc.9999999995-26-000936 ↗
2026-03-26EFFECTEFFECT (declared effective)Lyra Therapeutics, Inc.9999999995-26-000939 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2020-04-27S-1/Aregistration statement$14.00–$16.003,500,000-Nasdaq LYRA4primary document; range, price sentence, shares headline, proceeds computed, price outside the range dropped, cover names 4document ↗
2020-05-01424B4final prospectus$16.003,500,000$56,000,000Nasdaq LYRA4primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
ALTMAN MICHAEL SETHDirector62020–2024
ANDERSON EDWARD TDirector; Director,TenPercentOwner82020–2023
DAMORE RICHARD ATenPercentOwner42020–2023person page Fuzzy
EDELMAN JOSEPHDirector,TenPercentOwner; TenPercentOwner82020–2025
Edgerly-Pflug LauraOfficerSee Remarks22020
Elsey R DonOfficerCFO, Treasurer & Secretary32020–2021person page Fuzzy
Flint Jonathan ATenPercentOwner22020person page Fuzzy
LANGER ROBERTDirector32020
MCGUIRE TERRANCETenPercentOwner22020
MERRIFIELD C ANNDirector92020–2025
MOTT RICHARD WTenPercentOwner12020
NBVM GP, LLCTenPercentOwner42020–2023
North Bridge Venture Management VI, L.P.TenPercentOwner42020–2023
North Bridge Venture Management V, L.P.TenPercentOwner42020–2023
NORTH BRIDGE VENTURE PARTNERS V A LPTenPercentOwner42020–2023
NORTH BRIDGE VENTURE PARTNERS V-B LPTenPercentOwner42020–2023
North Bridge Venture Partners VI L PTenPercentOwner42020–2023
Noyes CorinneOfficerSee Remarks52020–2023
Palasis MariaDirector,OfficerPresident & CEO; Principal Executive Officer172020–2026
PERCEPTIVE ADVISORS LLCDirector,TenPercentOwner; TenPercentOwner82020–2025
PERCEPTIVE LIFE SCIENCES MASTER FUND LTDTenPercentOwner72020–2025
Perceptive LS (A), LLCTenPercentOwner72020–2025
Polaris Venture Management Co IV LLCTenPercentOwner22020
Polaris Venture Management Co. V, L.L.C.TenPercentOwner22020
POLARIS VENTURE PARTNERS ENTREPRENEURS FUND IV LPTenPercentOwner22020
Polaris Venture Partners Entrepreneurs' Fund V, L.P.TenPercentOwner22020
Polaris Venture Partners Founders' Fund V, L.P.TenPercentOwner22020
POLARIS VENTURE PARTNERS IV LPTenPercentOwner22020
Polaris Venture Partners Special Founders' Fund V, L.P.TenPercentOwner22020
Polaris Venture Partners V, L.P.TenPercentOwner22020
Poukalov KonstantinDirector62020–2024
Roberts CarmichaelTenPercentOwner22020
Smith W BradfordDirector72020–2026
WHITESIDES GEORGE MDirector32020
Levy GuyTenPercentOwner22020
Soleus Capital Group, LLCTenPercentOwner12020
Soleus Capital, LLCTenPercentOwner12020
Soleus Capital Master Fund, L.P.TenPercentOwner12020
Soleus PE GP I, LLCTenPercentOwner22020
Soleus Private Equity Fund I, L.P.TenPercentOwner22020
Soleus Private Equity GP I, LLCTenPercentOwner22020
Richard Robert E.OfficerSVP of R&D; SVP, Technical Operations52020–2023
Nelson Pamela E.OfficerSenior VP, Regulatory Affairs; SVP, Regulatory Affairs42020–2022
snyderman nancy lynn MDDirector82020–2025
Cavalier JasonOfficerChief Financial Officer; Principal Financial Officer102021–2026
Waksal HarlanDirector,OfficerExecutive Chair82022–2024
TOBIN JAMES RDirector52022–2025
Nieman RichardOfficerChief Medical Officer42022–2024
Bishop John EOfficerChief Technology Officer32023–2024

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2023-06-09Lyra Therapeutics, Inc.Biotechnology$50,000,008$50,000,008241
2022-04-26Lyra Therapeutics, Inc.Biotechnology$100,494,970$100,494,970341
2020-01-27Lyra Therapeutics, Inc.Other$28,049,999$28,049,999141
2016-11-28480 Biomedical, Inc.Other$5,999,999$5,999,99991

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Plan sponsorLYRA THERAPEUTICS, INC.MAForm 5500 (employee benefit plans)name and state
Federal award recipientLYRA THERAPEUTICS INCMAFederal spending (USAspending)name and state
Form D issuerLyra Therapeutics, Inc.MAForm D private offeringsCIK (EXACT)
IPO registrantTETRAPHASE PHARMACEUTICALS INCMAIPO registrations (S-1, F-1)same street address and ZIP code, 480 ARSENAL WAY 02472 (FUZZY: a shared address, not proof of a shared organization)
Patent assigneeLYRA THERAPEUTICS, INC.MAPatents (USPTO)name and state
SEC filerLyra Therapeutics, Inc.SEC filers (EDGAR)CIK (EXACT)
Trademark ownerLYRA THERAPEUTICS, INC.MATrademarks (USPTO)name and state
Person pageJonathan A FlintPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner)
Person pageR Don ElseyPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer)
Person pageRichard A D'AmorePeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Surgical & Medical Instruments & Apparatus, MA first:

More with this interest.

In other datasets, the same topic (Technology) in MA:

Interests: Surgical & Medical Instruments & Apparatus · Technology